PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD-1 gene

Gene

Volumn 638, Issue , 2018, Pages 20-25

  Berger, Kristin Nicole ^a,b   Pu, Jeffrey Jiayu ^a,c  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

Human Programmed Cell Death 1 (hPD 1) gene; Hyperprogressive disease status; Immune checkpoint inhibition; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; BIOLOGICAL MARKER; BMS 936559; DABRAFENIB; DOCETAXEL; DURVALUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PROGRAMMED DEATH 1 RECEPTOR; TRAMETINIB; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; DRUG EFFICACY; GENE STRUCTURE; GENOME ANALYSIS; HUMAN; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; GENETICS; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 85032164595     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2017.09.050     Document Type: Review

References (59)

1. Akbay, E.A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J.H., Christensen, C.L., Mikse, O.R., Cherniack, A.D., Beauchamp, E.M., Pugh, T.J., Wilkerson, M.D., Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3:12 (2013), 1355–1363.
2. Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., Schuster, S.J., Millenson, M.M., Cattry, D., Freeman, G.J., Rodig, S.J., PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 372:4 (2015), 311–319.
3. Blank, C., Brown, I., Peterson, A.C., Spiotto, M., Iwai, Y., Honjo, T., Gajewski, T.F., PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8 + T cells. Cancer Res. 64:3 (2004), 1140–1145.
4. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., Barlesi, F., Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N. Engl. J. Med. 373:17 (2015), 1627–1639.
5. Brahmer, J.R., Drake, C.G., Wollner, I., Powderly, J.D., Picus, J., Sharfman, W.H., Stankevich, E., Pons, A., Salay, T.M., McMiller, T.L., Gilson, M.M., Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28:19 (2010), 3167–3175.
6. Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., Waterhouse, D., Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N. Engl. J. Med. 373:2 (2015), 123–135.
7. Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S., Chaput, N., Eggermont, A.M., Marabelle, A., Soria, J.C., Ferté, C., Hyperprogressive disease (HPD) is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin. Cancer Res. 23:8 (2017), 1920–1928 (Apr 15).
8. Chen, L., Han, X., Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J. Clin. Invest. 125:9 (2015), 3384–3391.
9. Chiou, V.L., Burotto, M., Pseudoprogression and immune-related response in solid tumors. J. Clin. Oncol. 33:31 (2015), 3541–3543.
10. Disis, M.L., Patel, M.R., Pant, S., Hamilton, E.P., Lockhart, A.C., Kelly, K., Beck, J.T., Gordon, M.S., Weiss, G.J., Taylor, M.H., Chaves, J., Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN solid tumor phase Ib trial: safety and clinical activity. J. Clin. Oncol., 2016, 34 (suppl; abstract 5533).
11. Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., Roche, P.C., Lu, J., Zhu, G., Tamada, K., Lennon, V.A., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8:8 (2002), 793–800.
12. Drake, C.G., Jaffee, E., Pardoll, D.M., Mechanisms of immune evasion by tumors. Adv. Immunol. 90 (2006), 51–81.
13. Fesnak, A.D., June, C.H., Levine, B.L., Engineered T cells: the promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 16:9 (2016), 566–581.
14. Finger, L.R., Pu, J., Wasserman, R., Vibhakar, R., Louie, E., Hardy, R.R., Burrows, P.D., Billips, L.G., 1999. The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene 197–203 (1997), 177–253.
15. Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L.J., Malenkovich, N., Okazaki, T., Byrne, M.C., Horton, H.F., Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192:7 (2000), 1027–1034.
16. Gandini, S., Massi, D., Mandalà, M., PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 100 (2016), 88–98.
17. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., Carcereny, E., Pembrolizumab for the treatment of non–small-cell lung cancer. N. Engl. J. Med. 372:21 (2015), 2018–2028.
18. Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., Matsumura, N., Safety and antitumor activity of anti–PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33:34 (2015), 4015–4022.
19. Hodi, F.S., Hwu, W.J., Kefford, R., Weber, J.S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T.C., Joshua, A.M., Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34:13 (2016), 1510–1517.
20. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., Seja, E., Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165:1 (2016), 35–44.
21. Hu-Lieskovan, S., Mok, S., Moreno, B.H., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E.M., Koya, R.C., Graeber, T.G., Comin-Anduix, B., Ribas, A., Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma. Sci. Transl. Med., 7(279), 2015, 279ra41.
22. Ishida, Y., Agata, Y., Shibahara, K., Honjo, T., Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J., 11(11), 1992, 3887.
23. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., Minato, N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. 99:19 (2002), 12293–12297.
24. Iwai, Y., Hamanishi, J., Chamoto, K., Honjo, T., Cancer immunotherapies targeting the PD-1 signaling pathway. J. Biomed. Sci., 24(1), 2017, 26.
25. Kato, S., Goodman, A.M., Walavalkar, V., Barkauskas, D.A., Sharabi, A., Kurzrock, R., Hyper-progressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin. Cancer Res., 2017, 3133.
26. Lahmar, J., Facchinetti, F., Koscielny, S., Ferte, C., Mezquita, L., Bluthgen, M.V., Lindsay, C.R., Adam, J., Planchard, D., Soria, J.C., Besse, B., Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC). J. Clin. Oncol., 34, 2016 (suppl; abstract 9034).
27. Latchman, Y., Wood, C.R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A.J., Brown, J.A., Nunes, R., Greenfield, E.A., PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2:3 (2001), 261–268.
28. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., Biedrzycki, B., PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372:26 (2015), 2509–2520.
29. Ledford, H., Promising cancer drugs may speed tumours in some patients. Nature, 544(7648), 2017, 13.
30. Ma, W., Gilligan, B.M., Yuan, J., Li, T., Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J. Hematol. Oncol., 9(1), 2016, 47.
31. Marzec, M., Zhang, Q., Goradia, A., Raghunath, P.N., Liu, X., Paessler, M., Wang, H.Y., Wysocka, M., Cheng, M., Ruggeri, B.A., Wasik, M.A., Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc. Natl. Acad. Sci. 105:52 (2008), 20852–20857.
32. Massard, C., Gordon, M.S., Sharma, S., Rafii, S., Wainberg, Z.A., Luke, J., Curiel, T.J., Colon-Otero, G., Hamid, O., Sanborn, R.E., O'Donnell, P.H., Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34:26 (2016), 3119–3125.
33. Mellman, I., Coukos, G., Dranoff, G., Cancer immunotherapy comes of age. Nature 480:7378 (2011), 480–489.
34. Nishimura, H., Nose, M., Hiai, H., Minato, N., Honjo, T., Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:2 (1999), 141–151.
35. Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., Honjo, T., Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:5502 (2001), 319–322.
36. Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., Honjo, T., PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. 98:24 (2001), 13866–13871.
37. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:4 (2012), 252–264.
38. Parsa, A.T., Waldron, J.S., Panner, A., Crane, C.A., Parney, I.F., Barry, J.J., Cachola, K.E., Murray, J.C., Tihan, T., Jensen, M.C., Mischel, P.S., Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13:1 (2007), 84–88.
39. Petroff, M.G., Chen, L., Phillips, T.A., Hunt, J.S., B7 family molecules: novel immunomodulators at the maternal-fetal interface. Placenta 23 (2002), S95–S101.
40. Ribas, A., Robert, C., Hodi, F.S., Wolchok, J.D., Joshua, A.M., Hwu, W.J., Weber, J.S., Zarour, H.M., Kefford, R., Loboda, A., Albright, A., Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J. Clin. Oncol., 33, 2015 (suppl; abstract 3001).
41. Rizvi, N.A., Mazières, J., Planchard, D., Stinchcombe, T.E., Dy, G.K., Antonia, S.J., Horn, L., Lena, H., Minenza, E., Mennecier, B., Otterson, G.A., Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 16:3 (2015), 257–265.
42. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., Miller, M.L., Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science 348:6230 (2015), 124–128.
43. Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J.C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., Savage, K.J., Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372:4 (2015), 320–330.
44. Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., Daud, A., Carlino, M.S., McNeil, C., Lotem, M., Larkin, J., Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372:26 (2015), 2521–2532.
45. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., Van Der Heijden, M.S., Balar, A.V., Necchi, A., Dawson, N., O'Donnell, P.H., Balmanoukian, A., Loriot, Y., Srinivas, S., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:10031 (2016), 1909–1920.
46. Rosenwald, A., Wright, G., Leroy, K., Yu, X., Gaulard, P., Gascoyne, R.D., Chan, W.C., Zhao, T., Haioun, C., Greiner, T.C., Weisenburger, D.D., Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 198:6 (2003), 851–862.
47. Roszik, J., Haydu, L.E., Hess, K.R., Oba, J., Joon, A.Y., Siroy, A.E., Karpinets, T.V., Stingo, F.C., Baladandayuthapani, V., Tetzlaff, M.T., Wargo, J.A., Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Med., 14(1), 2016, 168.
48. Saada-Bouzid, E., Defaucheux, C., Karabajakian, A., Palomar Coloma, V., Servois, V., Paoletti, X., Even, C., Fayette, J., Guigay, J., Loirat, D., Romano, E., Tumor's flare-up and patterns of recurrence in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with anti-PD1/PD-L1 inhibitors. J. Clin. Oncol., 34, 2016 (suppl; abstract 6072).
49. Spira, A.I., Park, K., Mazières, J., Vansteenkiste, J.F., Rittmeyer, A., Ballinger, M., Waterkamp, D., Kowanetz, M., Mokatrin, A., Fehrenbacher, L., Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J. Clin. Oncol., 33, 2015 (suppl; abstract 8010).
50. Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., Gajewski, T.F., Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8 + T cells. Sci. Transl. Med., 5(200), 2013, 200ra116.
51. Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., Chen, S., Klein, A.P., Pardoll, D.M., Topalian, S.L., Chen, L., Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med., 4(127), 2012, 127ra37.
52. Taube, J.M., Klein, A.P., Brahmer, J.R., Xu, H., Pan, X., Kim, J.H., Chen, L., Pardoll, D.M., Topalian, S.L., Anders, R.A., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res., 2014 (pp.clincanres-3271).
53. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 2012:366 (2012), 2443–2454.
54. Topalian, S.L., Sznol, M., McDermott, D.F., Kluger, H.M., Carvajal, R.D., Sharfman, W.H., Brahmer, J.R., Lawrence, D.P., Atkins, M.B., Powderly, J.D., Leming, P.D., Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32:10 (2014), 1020–1030.
55. Vanneman, M., Dranoff, G., Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12:4 (2012), 237–251.
56. Weber, J.S., D'Angelo, S.P., Minor, D., Hodi, F.S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N.I., Miller, W.H., Lao, C.D., Linette, G.P., Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 16:4 (2015), 375–384.
57. Wolchok, J.D., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., Humphrey, R., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15:23 (2009), 7412–7420.
58. Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., Saito, T., Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J. Exp. Med. 209:6 (2012), 1201–1217.
59. Zhang, X., Sharma, P.K., Peter Goedegebuure, S., Gillanders, W.E., Personalized cancer vaccines: targeting the cancer mutanome. Vaccine 35:7 (2017), 1094–1100 (Feb 15).